Generic Name and Formulations:
Amlodipine (as besylate), olmesartan medoxomil; 5mg/20mg, 10mg/20mg, 5mg/40mg, 10mg/40mg; tabs.
Indications for AZOR :
Individualize. Initially 5/20mg once daily; may increase after 1–2 weeks up to max 10/40mg daily. ≥75yrs or hepatic impairment: initial therapy not recommended.
Concomitant aliskiren in patients with diabetes.
Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.
Fetal toxicity may develop; discontinue if pregnancy is detected. Volume/salt depleted. Severe obstructive coronary disease. Severe aortic stenosis. Severe hepatic or renal impairment. Renal artery stenosis. Consider discontinuing if sprue-like enteropathy develops and no other etiology is identified. Monitor electrolytes periodically. Elderly (may need lower initial dose of amlodipine). Neonates. Pregnancy (Cat.D); monitor. Nursing mothers: not recommended.
Calcium channel blocker (CCB) + angiotensin II receptor blocker (ARB).
See Contraindications. Potentiates simvastatin; limit simvastatin dose to 20mg/day. May potentiate cyclosporine, tacrolimus, lithium; monitor levels. Potentiated by CYP3A4 inhibitors; may need dose reduction. Antagonized by NSAIDs (including selective COX-2 inhibitors); may impair renal function (monitor). Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; monitor closely. Concomitant aliskiren in renal impairment (CrCl <60mL/min): not recommended. Consider taking at least 4hrs before colesevelam HCl dose. Monitor BP with CYP3A4 inducers.
Edema, dizziness; headache, hypotension, rash, pruritus, palpitation, urinary frequency, nocturia, hepatic or renal dysfunction, decreased hematocrit, decreased hemoglobin, hyperkalemia (rare).
Amlodipine: hepatic; 93% protein bound. Olmesartan: 99% protein bound.
Renal (primary); fecal.
Tabs—30, 90, 100, 1000
Clinical Pain Advisor Articles
- Analyzing Coverage of Nonpharmacologic Treatments for Low Back Pain
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Predicting the Magnitude of Placebo Analgesia in Chronic Pain
- Dsuvia Gains FDA Approval: We Want to Hear Your Thoughts
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- Half of the Responders to Our Poll Agree With the Approval of Dsuvia: We Want to Hear From You
- Daily Alcohol Use May Drive Chronic Pain in Adults With HIV
- Tools to Address the Opioid Crisis
- AHA/ACC Release Updated Guidelines for Cholesterol Management
- Women Fed Soy Formula as Infants More Likely to Experience Menstrual Pain